Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-11 |
2024-09 |
-0.06 |
N/A |
N/A |
N/A |
2024-08-12 |
2024-06 |
-0.05 |
-0.05 |
N/A |
N/A |
2024-05-13 |
2024-03 |
-0.07 |
-0.05 |
0.02 |
28.57% |
2024-04-01 |
2023-12 |
-0.05 |
-0.06 |
-0.01 |
-20.00% |
2023-11-13 |
2023-09 |
0 |
-0.05 |
N/A |
N/A |
2023-08-14 |
2023-06 |
0 |
-0.06 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-07 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
2020-09-16 |
Ascendiant Capital |
Upgrade |
|
Buy |
2019-12-17 |
Maxim Group |
Upgrade |
Hold |
Buy |
2018-01-25 |
Maxim Group |
Upgrade |
|
Buy |
2013-10-06 |
Sidoti & Co. |
Downgrade |
Buy |
Neutral |
2013-04-14 |
Sidoti & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2016-03-08 |
CHEN SHU-CHIH |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2013-05-14 |
CROSS ALEXANDER DENNIS |
Director |
0.00 |
Purchase |
2024-04-09 |
FINN JONATHAN F. |
Director |
25.00K |
Purchase |
2017-11-14 |
GUSE KYLE |
General Counsel |
10.00K |
Purchase |
2016-03-08 |
QUAY STEVEN C |
Chief Executive Officer |
0.00 |
Purchase |
2017-04-16 |
REMMEL H LAWRENCE |
Director |
3.13K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
5.68M |
7.15M |
4.51% |
2023-06-29 |
Blackrock Inc. |
2.90M |
3.65M |
2.30% |
2023-06-29 |
Laurion Capital Management, LP |
2.23M |
2.80M |
1.77% |
2023-06-29 |
Geode Capital Management, LLC |
1.11M |
1.40M |
0.88% |
2023-06-29 |
Renaissance Technologies, LLC |
1.07M |
1.35M |
0.85% |
2023-06-29 |
State Street Corporation |
436.27K |
549.70K |
0.35% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.78M |
4.76M |
3.00% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.66M |
2.10M |
1.32% |
2023-05-30 |
Fidelity Extended Market Index Fund |
659.95K |
613.75K |
0.52% |
2023-05-30 |
BlackRock Advantage Small Cap Core Fund |
340.50K |
316.67K |
0.27% |
2023-05-30 |
Fidelity Total Market Index Fund |
182.91K |
170.11K |
0.15% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
142.17K |
132.22K |
0.11% |
Split |
Date |
1 : 12 |
2018-04-20 |
1 : 15 |
2016-08-26 |